The ULF is happy to share a community letter from Vigil regarding their potential treatment option for those affected by ALSP! Here is a preview but click the links below to read the whole letter and press release.
“Dear ALSP Community Members:
This week we announced positive interim data from IGNITE, our Phase 2 clinical trial evaluating iluzanebart (VGL101) for treatment in ALSP. These results represent the first data reported from a clinical trial in people living with ALSP and they also reaffirm our belief in the potential of iluzanebart (VGL101) as a novel treatment option.” …